Next Article in Journal
Reconsidering the Turnaround Times for BRAF V600 Mutation Analysis in Non-Small-Cell Lung Cancer: A Molecular Diagnosis in One Day Is Achievable for Rapid Treatment Choices
Previous Article in Journal
Canadian Lung Cancer Conference 2019
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 26
Issue 4
10.3747/co.26.5565
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Updates from the 2019 American Society of Clinical Oncology and European Hematology Association Annual Meetings: A Canadian Perspective on High-Risk Cytogenetics in Multiple Myeloma

by
R. LeBlanc
1,
K. Song
2,
D. White
3,
A. Christofides
4,* and
S. Doucette
4
1
Université de Montréal and Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada
2
University of British Columbia and Vancouver General Hospital, Vancouver, BC, Canada
3
Dalhousie University and Queen Elizabeth iiHealth Sciences Centre, Halifax, NS, Canada
4
IMPACT Medicom Inc., Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2019, 26(4), 581-594; https://doi.org/10.3747/co.26.5565
Submission received: 3 May 2019 / Revised: 11 June 2019 / Accepted: 8 July 2019 / Published: 1 August 2019

Abstract

The 2019 annual meetings of the American Society of Clinical Oncology and the European Hematology Association took place, respectively, in Chicago, Illinois, 31 May–4 June, and in Amsterdam, Netherlands, 13–16 June. At the meetings, results from key studies on the treatment of patients with relapsed or refractory multiple myeloma with high-risk cytogenetics were presented. Our meeting report describes those studies and includes interviews with investigators and commentaries by Canadian hematologists about the potential impact on Canadian practice.
Keywords: relapsed disease; refractory disease; multiple myeloma; high-risk cytogenetics relapsed disease; refractory disease; multiple myeloma; high-risk cytogenetics

Share and Cite

MDPI and ACS Style

LeBlanc, R.; Song, K.; White, D.; Christofides, A.; Doucette, S. Updates from the 2019 American Society of Clinical Oncology and European Hematology Association Annual Meetings: A Canadian Perspective on High-Risk Cytogenetics in Multiple Myeloma. Curr. Oncol. 2019, 26, 581-594. https://doi.org/10.3747/co.26.5565

AMA Style

LeBlanc R, Song K, White D, Christofides A, Doucette S. Updates from the 2019 American Society of Clinical Oncology and European Hematology Association Annual Meetings: A Canadian Perspective on High-Risk Cytogenetics in Multiple Myeloma. Current Oncology. 2019; 26(4):581-594. https://doi.org/10.3747/co.26.5565

Chicago/Turabian Style

LeBlanc, R., K. Song, D. White, A. Christofides, and S. Doucette. 2019. "Updates from the 2019 American Society of Clinical Oncology and European Hematology Association Annual Meetings: A Canadian Perspective on High-Risk Cytogenetics in Multiple Myeloma" Current Oncology 26, no. 4: 581-594. https://doi.org/10.3747/co.26.5565

Article Metrics

Back to TopTop